MTM(SH:688029) GOLDEN SUN SECURITIES·2025-08-18 00:45Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company demonstrated robust performance in H1 2025, with revenue reaching 1.565 billion yuan, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, up 17.04% [1] - Innovative products showed significant growth, with revenue from new products reaching 110 million yuan, a nearly 40% increase year-on-year, and overseas innovative products growing even more impressively [2][3] - The company is expanding its global service capabilities and has made significant progress in its overseas market, achieving 910 million yuan in overseas revenue, a 44.85% increase, with overseas revenue now accounting for 58% of total revenue [3] Summary by Sections Financial Performance - In H1 2025, the company achieved operating income of 1.565 billion yuan, with a quarterly breakdown showing Q2 revenue of 866 million yuan, a 21.36% year-on-year increase [1] - The company’s core product transition is expected to drive gross margin improvement, with gross margins for various product lines showing slight declines but potential for recovery as core products are switched [2] Product and Market Development - The company’s innovative products, particularly in the visualization category, are expected to contribute significantly to future revenue growth, with the second-generation cholangioscope anticipated to launch next year [4] - The company has successfully expanded its overseas market presence to over 90 countries, with notable growth in the Americas and Europe, particularly after acquiring a 51% stake in Creo Medical S.L.U. [3] Future Projections - Revenue forecasts for 2025-2027 are projected at 3.341 billion, 3.993 billion, and 4.754 billion yuan, respectively, with corresponding net profits of 671 million, 807 million, and 968 million yuan [4] - The report anticipates a steady increase in earnings per share (EPS) from 3.57 yuan in 2025 to 5.15 yuan in 2027, reflecting strong growth potential [5]